Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02863926 · ClinicalTrials.gov registry record · Phase 1

Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)

A Phase 1 study of Peripheral Artery Disease and Critical Limb Ischemia, sponsored by Michael Murphy.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT02863926 is a Phase 1 study of Peripheral Artery Disease and Critical Limb Ischemia that has completed, run by Michael Murphy. The registered enrollment target is 6 participants, below the 127-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02863926, a Phase 1 study of Peripheral Artery Disease and Critical Limb Ischemia, has completed, sponsored by Michael Murphy.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Patients scheduled for major extremity lower amputation to receive bone marrow cells (cBMA) injected IM in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery.

Interventions

  • BIOLOGICAL Injection of cBMA aspirate into the index leg

Study Locations (1)

Indiana

  • Indiana University School of Medicine - Indianapolis

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2017-01-06
Est. Completion 2018-07-27
Phase Phase 1

Sponsor

Michael Murphy

1 total trials

What the Registry Record Tells You About NCT02863926

The ClinicalTrials.gov registry entry for NCT02863926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (95% lower). The listed sponsor is Michael Murphy, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Injection of cBMA aspirate into the index leg is the first listed.

NCT02863926 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT02863926 about?

NCT02863926 is a clinical study titled "Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)". Patients scheduled for major extremity lower amputation to receive bone marrow cells (cBMA) injected IM in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery.

What is the current status of trial NCT02863926?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-01-06. Estimated completion is 2018-07-27.

What conditions does trial NCT02863926 study?

This clinical trial studies the following conditions: Peripheral Artery Disease, Critical Limb Ischemia, Vascular Disease.

What interventions are being tested in trial NCT02863926?

The interventions under investigation include: Injection of cBMA aspirate into the index leg (BIOLOGICAL).

Who is sponsoring clinical trial NCT02863926?

This trial is sponsored by Michael Murphy, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02863926 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.